Evaluation and Management of Chronic Pulmonary Thromboembolic Disease
Authors:
- Michael L. ScharfMSMichael L. Scharf
- MdMDMd
- 1 August 2011
- journal article
- review article
- Published by Taylor & Francis in Hospital Practice
- Vol. 39 (3) , 50-61
Abstract
Pulmonary embolism (PE) is common and the majority of patients survive the acute event. Survivors are at increased risk for adverse outcomes, including persistent thrombi, recurrent embolism, chronic thromboembolic pulmonary hypertension (CTEPH), and death. Anticoagulation protects against recurrence, which has a high mortality rate. The recommended duration of anticoagulation for patients with reversible PE risk factors is 3 months. For patients with idiopathic PE or persistent risk factors, extended duration of anticoagulation is preferred, balanced with an individual patient's risk of hemorrhage, which in itself is a major cause of morbidity and mortality. Among patients with malignancy who develop venous thromboembolism (VTE), low-molecular-weight heparin is preferred over oral vitamin K antagonists in the first 6 months. Thereafter, anticoagulation should be continued indefinitely with either low-molecular-weight heparin or oral vitamin K antagonists. Inferior vena cava filters are not routinely recommended and should only be used in patients who have a contraindication to anticoagulation. Patients who have had VTE and with persistent or recurrent dyspnea should be evaluated for recurrence of VTE or development of CTEPH. Patients with recurrent VTE should be anticoagulated indefinitely. Routine screening for CTEPH in asymptomatic patients is not recommended. Echocardiography often provides the first indication of the presence of pulmonary hypertension. Once presence of CTEPH is established by right-sided heart catheterization and perfusion imaging (ie, ventilation/perfusion scintigraphy, computed tomography angiography, or pulmonary angiography), patients should be referred early to a center with expertise, as it is potentially surgically curable by pulmonary endarterectomy. Those who are deemed inoperable after being evaluated may gain symptomatic benefit from drugs approved for idiopathic pulmonary arterial hypertension. Lung transplantation may also be an option for patients who are not candidates for pulmonary endarterectomy.Keywords
This publication has 91 references indexed in Scilit:
- Comparison of risk profile and clinical outcome of patients after acute pulmonary embolism in university and non‐university hospitalsJournal of Thrombosis and Haemostasis, 2010
- Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolismHaematologica, 2010
- Venous Thromboembolism After Removal of Retrievable Inferior Vena Cava FiltersCardioVascular and Interventional Radiology, 2009
- High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertensionBlood, 2009
- Death and Disability from Warfarin-Associated Intracranial and Extracranial HemorrhagesThe American Journal of Medicine, 2007
- Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trialBMJ, 2007
- Guidelines on use of vena cava filtersBritish Journal of Haematology, 2006
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary EmbolismNew England Journal of Medicine, 1997
- SKIN NECROSIS WITH A LOW MOLECULAR WEIGHT HEPARINBritish Journal of Haematology, 1992